Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| LDLR- |
RCV000238094 | SCV000294761 | likely pathogenic | Hypercholesterolemia, familial, 1 | 2016-03-25 | criteria provided, single submitter | literature only | |
| Ambry Genetics | RCV002338786 | SCV002644915 | likely pathogenic | Cardiovascular phenotype | 2019-09-04 | criteria provided, single submitter | clinical testing | The p.D172E variant (also known as c.516C>G), located in coding exon 4 of the LDLR gene, results from a C to G substitution at nucleotide position 516. The aspartic acid at codon 172 is replaced by glutamic acid, an amino acid with highly similar properties. This alteration (also described as legacy p.D151E) and close match p.D172E (c.516C>A) have been reported in patients with familial hypercholesterolemia (Chiou KR et al. Am. J. Cardiol., 2010 Jun;105:1752-8; Du R et al. Springerplus, 2016 Dec;5:2095; Xiang R et al. Atherosclerosis, 2017 Feb;258:84-88). Additional alterations at this position have also been reported in individuals with familial hypercholesterolemia (Thiart R et al. J. Med. Genet., 2000 Jul;37:514-9; Pongrapeeporn KU et al. J Med Assoc Thai, 2000 Nov;83 Suppl 2:S66-73; Leren TP et al. Semin Vasc Med, 2004 Feb;4:75-85; Dušková L et al. Atherosclerosis, 2011 May;216:139-45). This amino acid position is well conserved in available vertebrate species; however, glutamic acid is the reference amino acid in other vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic. |